Lupin receives tentative USFDA approval for Sitagliptin Tablets
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
The product will be manufactured at Lupin's Pithampur facility in India
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
Almost 300 million people globally have chronic hepatitis B
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
Subscribe To Our Newsletter & Stay Updated